USANA Beats FY25 Sales Guidance, Projects FY26 Growth Driven by Acquisitions

summarizeSummary

USANA Health Sciences announced preliminary fiscal year 2025 net sales above guidance and provided initial fiscal year 2026 net sales outlook, projecting overall growth driven by its acquired businesses.

check_boxKey Events

• Preliminary FY25 Net Sales Beat

  The company anticipates preliminary consolidated net sales of approximately $925 million for fiscal year 2025, exceeding its most recently issued guidance of approximately $920 million.

• Initial FY26 Net Sales Guidance

  USANA issued initial net sales guidance for fiscal year 2026 in the range of $925 million to $1.0 billion.

• Core Business Decline, Acquisition Growth

  The core nutritional business (USANA) is projected to decline to $720-$765 million in FY26 from $777 million in FY25, while Hiya and Rise Wellness are expected to grow significantly to $140-$155 million and $65-$80 million, respectively.

• Strategic Investments in Growth Segments

  The company plans meaningful investments in inventory, capital expenditures, and working capital for Rise Wellness and Hiya to support their early growth stages, with Rise Wellness expected to be at breakeven operating margins in fiscal year 2026.

auto_awesomeAnalysis

USANA Health Sciences reported preliminary fiscal year 2025 net sales that exceeded its previous guidance, indicating stronger-than-expected performance. For fiscal year 2026, the company issued initial net sales guidance projecting overall growth, primarily fueled by significant expansion in its Hiya and Rise Wellness segments. While the core nutritional business is anticipated to see a slight decline, the substantial growth in acquired brands, coupled with strategic investments, signals a shift in the company's revenue drivers and future growth strategy. Investors should monitor the execution of these growth initiatives and their impact on overall profitability.